:::

詳目顯示

回上一頁
題名:加速失敗時間模式分析新發乳癌病患併發血栓栓塞對其存活的影響
書刊名:臺灣公共衛生雜誌
作者:王南天蘇慧芳 引用關係李佩珍 引用關係張正雄 引用關係林寬佳 引用關係謝碧晴 引用關係
作者(外文):Wang, Nan-tenSu, Hui-fangLee, Pei-chenChang, Cheng-shyongLin, Kuan-chiaHsieh, Pi-ching
出版日期:2014
卷期:33:6
頁次:頁582-596
主題關鍵詞:血栓栓塞存活加速失敗時間模型Thromboembolic eventsSurvivalAccelerated failure time model
原始連結:連回原系統網址new window
相關次數:
  • 被引用次數被引用次數:期刊(0) 博士論文(0) 專書(0) 專書論文(0)
  • 排除自我引用排除自我引用:0
  • 共同引用共同引用:2
  • 點閱點閱:31
目標:血栓栓塞併發症(TEEs)為乳癌併發症主要之一且增加死亡風險,本研究擬探討台灣新發乳癌病患併發血栓栓塞之相關因素及對其兩年存活的影響。方法:本回溯性世代研究使用1997至2010年全民健康保險研究資料庫。以Poisson分佈探討2000到2008年新發乳癌世代觀察兩年其併發TEEs的發生情形。透過propensity socre匹配後再以Accelerated Failure Time Model檢視有無併發症病患對其兩年存活之影響。結果:2000-2008年新發乳癌世代共80,598人,罹癌確診後兩年內併發TEEs之累積發生率1.78%(95% CI = 1.74-1.82),且第一個半年併發症發生密度為1.38發生事件數/每100個人年。併發TEEs危險因子有年齡(≧65歲比<45歲adjusted incidence rate ratio [adj. IRR] = 3.87,95% CI = 3.80-3.93),共病指數(≧3分比0分adj. IRR = 1.96,95% CI = 1.93-2.00),有高血壓病史(adj. IRR = 1.43,95% CI = 1.41-1.45),有乳房手術者(adj. IRR = 1.47,95% CI = 1.45-1.49),接受放射線治療者(adj. IRR = 1.29,95% CI = 1.28-1.31),接受化學藥物治療者(adj. IRR = 1.40,95% CI = 1.38-1.42),醫院層級(地區醫院比醫學中心adj. IRR = 1.13,95% CI = 1.11-1.15)。AFT model分析顯示在控制其他變項後,有併發TEEs者比無者有較高比例的兩年死亡風險(adjusted Rate Ratio = 2.55, 95% CI = 2.24-2.91),且風險隨時間增加而增加。結論:新發乳癌病患併發TEEs會增加其死亡風險。醫療專業人員者可針對易併發TEE之危險群(如年長、共病指數高、有高血壓、接受乳癌手術、接受化療放療),即早警覺並提供適當的預防措施以利降低併發症的發生及提升癌症照護品質。
Objectives: Thromboembolic events (TEEs) are major complications affecting breast cancer patients, and are associated with increased mortality. The purpose of this study was to determine the incidence and risk factors for developing a new TEE in a population-based cohort of breast cancer patients, and also to determine the effect of TEEs on 2-year survival. Methods: A retrospective cohort study was conducted between 1997-2010 using the National Health Insurance Research Database in Taiwan. The incidence of TEEs amongst 2000-2008 breast cancer cohorts and the associated risk factors were determined based on the Poisson distribution. Propensity score matching was used to determine the effect of TEEs on 2-year survival through accelerated failure-time (AFT) model analysis. Results: Amongst 80,598 patients with breast cancer between 2000 and 2008, the 2-year cumulative TEE incidence was 1.78%, with a rate of 1.38 events/100 patient-years during the first 6 months. Based on a multivariate model, significant predictors of developing TEEs within 2 years were age (adjusted incidence rate ratio [aIRR] = 3.87 if ≧ 65 years vs. <45 years; 95% CI = 3.80-3.93), co-morbidity (aIRR = 1.96 if ≧3 vs. 0, 95% CI = 1.93-2.00), hypertension (aIRR = 1.43 if yes vs. no, 95% CI = 1.41-1.45), history of breast surgery (aIRR = 1.47 if yes vs. no, 95% CI = 1.45-1.49), history of radiotherapy (aIRR = 1.29 if yes vs. no, 95% CI = 1.28-1.31), history of chemotherapy (aIRR = 1.40 if yes vs. no, 95% CI = 1.38-1.42), and type of hospital (aIRR = 1.13 if district medical center vs. patient medical center 95% CI = 1.11-1.15). Based on AFT model analysis, and after controlling for other variables, patients with TEEs had a higher risk of 2-year death than those without TEEs (aRR = 2.55, 95% CI = 2.24-2.91) and had an increased hazard ratio over time. Conclusions: Breast cancer patients with TEEs have a higher risk of death. Early detection of risk factors of TEEs, such as older age, more co-morbidities, hypertension, and histories of surgery, chemotherapy, and radiotherapy) and appropriate preventive care should be provided by health professionals for decreasing the complications and improving the quality of cancer care.
期刊論文
1.Caine, G. J.、Stonelake, P. S.、Rea, D.、Lip, G. Y.(2003)。Coagulopathic complications in breast cancer。Cancer,98,1578-1586。  new window
2.Chew, H. K.、Wun, T.、Harvey, D. J.、Zhou, H.、White, R. H.(2007)。Incidence of venous thromboembolism and the impact on survival in breast cancer patients。J Clin Oncol,25,70-76。  new window
3.Khorana, A. A.、Francis, C. W.、Culakova, E.、Kuderer, N. M.、Lyman, G. H.(2007)。Frequency, risk factors, and trends for venous thromboembolism among hospitalized cancer patients。Cancer,110,2339-2346。  new window
4.Rickles, F. R.、Edwards, R. L.、Barb, C.、Cronlund, M.(1983)。Abnormalities of blood coagulation in patients with cancer. Fibrinopeptide A generation andtumorgrowth。Cancer,51,301-307。  new window
5.McDonald, C. C.、Alexander, F. E.、Whyte, B. W.、Forrest, A. P.、Stewart, H. J.(1995)。Cardiac and vascular morbidity in women receiving adjuvant tamoxifen for breast cancer in a randomized trial。BMJ,311,977-980。  new window
6.Andtbacka, H. I.、Babiera, G.、Singletary, S. E.(2006)。Incidence and prevention of venous thromboembolism in patients undergoing breast cancer surgery and treated according to clinical pathways。Ann Surg,243,96-101。  new window
7.Chavez-MacGregor, M.、Zhao, H.、Kroll, M.(2011)。Risk factors and incidence of thromboembolic events (TEEs) in older men and women with breast cancer。Ann Oncol,22,2394-2402。  new window
8.Hooning, M. J.、Dorresteijn, D. A.、Aleman, M. P.(2006)。Decreased risk of stroke among 10-year survivors of breast cancer。J Clin Oncol,24,5388-5394。  new window
9.Khorana, A. A.、Francis, C. W.、Culakova, E.、Fisher, R. I.、Kuderer, N. M.、Lyman, G. H.(2006)。Thromboembolism in hospitalized neutropenic cancer patients。J Clin Oncol,24,484-490。  new window
10.梁逸歆、徐志宏(20110200)。Pulmonary Thromboembolism Related to Progression of Duodenal Adenocarcinoma。臺灣癌症醫學雜誌,27(1),37-41。  延伸查詢new window
11.王智慧、張君照、戴承正(20110800)。Deep Venous Thrombosis and Pulmonary Embolism in Pancreatic Cancer。臺灣癌症醫學雜誌,27(4),171-176。  延伸查詢new window
12.Ay, C.、Dunkler, D.、Marosi, C.(2010)。Prediction of venous thromboembolism in cancer patients。Blood,116,5377-5382。  new window
13.Nolan, L.、Darby, A.、Boleti, K.、Simmonds, P.(2011)。The incidence of symptomatic thromboembolism in patients receiving adjuvant anthracycline-based chemotherapy for early stage breast cancer。Breast,20,151-154。  new window
14.Cushman, M.、Tsai, A. W.、White, R. H.(2004)。Deep vein thrombosis and pulmonary embolism in two cohorts: the longitudinal investigation of thromboembolism etiology。Am J Med,117,19-25。  new window
15.Khorana, A. A.、Francis, C. W.、Culakova, E.、Lyman, G. H.(2005)。Risk factors for chemotherapy-associated venous thromboembolism in a prospective observational study。Cancer,104,2822-2829。  new window
16.Lyman, G. H.、Khorana, A. A.、Falanga, A.(2007)。American Society of Clinical Oncology guideline: recommendations for venous thromboembolism prophylaxis and treatment in patients with cancer。J Clin Oncol,25,5490-5505。  new window
17.Heit, J. A.、Silverstein, M. D.、Mohr, D. N.、Petterson, T. M.、O'Fallon, W. M.、Melton, L. J.(2000)。Risk factors for deep vein thrombosis and pulmonary embolism a population-based case-control study。Arch Intern Med,160,809-815。  new window
18.Heit, J. A.、O'Fallon, W. M.、Patterson, T. M.(2002)。Relative impact of risk factors for deep vein thrombosis and pulmonary embolism。Arch Intern Med,162,1245-1248。  new window
19.Deitcher, S. R.、Gomes, M. P. V.(2004)。The risk of venous thromboembolic disease associated with adjuvant hormone therapy for breast carcinoma。Cancer,101,439-449。  new window
20.Kyriazi, V.(2012)。Breast cancer as an acquired thrombophilic state。J Breast Cancer,15,148-156。  new window
21.Baum, M.、Budzar, A. U.、Cuzick, J.(2002)。Anastrozole alone or in combination with tamoxifen versus tamoxifen alone for adjuvant treatment of postmenopausal women with early breast cancer: first results of the ATAC randomised trial。Lancet,359,2131-2139。  new window
22.陳錫杰、蘇慧芳、李中一、賴美淑、謝碧晴(20100400)。醫師的遵循行為可促進病患的存活嗎?以臺灣非小細胞肺癌病患為例。臺灣公共衛生雜誌,29(2),118-130。new window  延伸查詢new window
圖書
1.衛生福利部國民健康署(2012)。民國98年癌症登記報告。臺北:衛生福利部國民健康署。  延伸查詢new window
2.Allison, P. D.(2004)。Survival Analysis Using SAS®: A Practical Guide。North Carolina:SAS Institute Inc.。  new window
其他
1.臺灣癌症登記中心。長期趨勢,http://tcr.cph.ntu.edu.tw/, 2014/06/29。  延伸查詢new window
2.衛生福利部。民國101死因統計年報,http://www.mohw.gov.tw/cht/DOS/DisplayStatisticFile.aspx?d=13718&s=1, 2014/06/29。  new window
3.The Joint Commission。Core measure sets,http://www.jointcommission.org/core_measure_sets.aspx, 2013/05/24。  new window
4.衛生福利部中央健保署(2011)。2011年全民健康保險統計動向,http://www.nhi.gov.tw/resource/Webdata/23838_1_%E5%85%A8%E6%B0%91%E5%81%A5%E5%BA%B7%E4%BF%9D%E9%9A%AA%E7%B5%B1%E8%A8%88%E5%8B%95%E5%90%91-2011%E5%B9%B4.pdf, 2013/06/20。  new window
 
 
 
 
第一頁 上一頁 下一頁 最後一頁 top
QR Code
QRCODE